MedCity News July 23, 2025
Pharmaceutical tariffs are coming, part of President Trump’s stated goal of bringing drug manufacturing back to the U.S. Untangling the sprawling, global supply chain will be complicated and expensive, and could inadvertently compete with other administration goals regarding drug pricing and availability.
It could be years before a cell therapy from Nkarta reaches autoimmune disease patients in the market, but CEO Paul Hastings still thinks about the impact of pharmaceutical tariffs here and now. With blood from healthy donors, Nkarta isolates immune cells called natural killer cells, then engineers them for a new therapeutic purpose. The donor material comes from the U.S. and Nkarta manufactures its therapies at its own site in South San Francisco, but it’s misleading to call...
Today's Sponsors
Today's Sponsor